Table 3.

Potential targets to inhibit the activation and proinflammatory effects of innate leukocytes known to be involved in the onset and progression of T1D

Pathway	Candidate agents
Inflammasomes	OLT1177, inzomelid, IZD334, withaferin-A
Chemokines	CXCL12 antibodies, SB225002, SB656933, reparixin, ladarixin, navarixin, danirixin, AZD5069, AZD8309
Formation of NETs (NETosis)	GSK484
Enzymes secreted by innate leukocytes
NE	AAT, silvelestat, AZD9668, BAY-678, BAY 85-8501
MPO	AZD5904, AZD3421, PF-06282999